Form 10-Q VERTEX PHARMACEUTICALS For: Jun 30
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Nasdaq, S&P dip, trading choppy as tech stocks fall
- Brent hits lowest since before start of Iran war as more tankers exit Hormuz, easing supply
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- JPMorgan raises S&P 500 target to 7,800, says earnings revision ’unprecedented’
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- UBS Reiterates Buy Rating on Snowflake Inc. (SNOW)
Vertex (VRTX) PT Raised to $576 at Wolfe Research
August 5, 2024 5:19 AM EDTWolfe Research analyst Andy Chen raised the price target on Vertex (NASDAQ: VRTX) to $576.00 (from $520.00) while maintaining a Outperform rating.
The analyst comments "Revenue & earnings in-line. Now what after the bull run? Little incremental news aside from two exhibits on T1D. Our... More
